Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

Inclusion Criteria: * histopathology confirmed DLBCL，with chronic hepatitis B before treatment * After systemic treatment, complete response has been achieved and complete response lasted within 1year before enrollment * The expected chemotherapy was completed and the laboratory indexes returned to normal * The absolute value of neutrophil ≥ 1.5 × 10 9 / L, platelet count≥ 90 × 10 9 / L, hemoglobin level≥ 90 g / L * Patients who cannot undergo hematopoietic stem cell transplantation for various reasons * 18-75 years old, both male and female * ECOG PS 0-1 * Body weight: male 67 ± 20 kg (47-87 kg), female 55 ± 20 kg (35-75 kg) * expected survival time ≥3 months * Voluntary written informed consent prior to trail screening Exclusion Criteria: * Pregnant and lactating women and women of childbearing age who are unwilling to take contraceptive measures * Patients with prolonged QTc interval (male \> 450ms, female \> 470ms), ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI) within 1 year, congestive heart failure (CHF), and coronary heart disease with symptoms requiring drug treatment * B-ultrasound showed that the width of the fluid dark area in the pericardial cavity was ≥ 10 mm at the end of diastolic period * Patients with previous or planned organ transplantation * Patients receiving symptomatic treatment for early myelotoxicity within 7 days before enrollment * HBV nucleic acid quantitation \> 103 IU / ml * Patients with activ…